Creative Medical Technology (CMT) filed a patent application covering synergy between intradiscal stem cell injections and stimulation of blood vessel formation around the spine. This expands on the company's issued U.S. Patent No. 9,598,673, which addresses injection of stem cells into the lower back to stimulate new blood vessel formation (angiogenesis).
CMT's technology uses biologic elements to stimulate angiogenesis and counteract deficient circulation that may contribute to disc degeneration. Study results released by Mesoblast have indicated that one intradiscal injection of 6 million Mesenchymal Precursor Cells yielded meaningful improvements in chronic low back pain and function that were durable for at least 36 months. By increasing circulation, CMT expects to modify the disc environment to give injected stem cells the optimal conditions for regeneration.
CMT seeks to partner with companies developing intradiscal stem cell therapeutics.